UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
PHARMACEUTICAL COMPANIES

ANI Pharmaceuticals

Rare disease and established pharmaceutical products maker

ANI Pharmaceuticals logo

ANI Pharmaceuticals

Pharmaceutical CompaniesBaudette, MN, United States

Rare disease and established pharmaceutical products maker

Visit Website

About ANI Pharmaceuticals

ANI Pharmaceuticals is a NASDAQ-listed integrated specialty pharmaceutical company (ticker: ANIP) focused on building a leading rare disease business. Operating across branded and generic prescription markets, the company develops, manufactures, and markets high-quality pharmaceuticals for patients with significant unmet needs.

The company's rare disease focus is a defining strategic pillar, with FDA-approved products including Cortrophin serving as a flagship within its branded portfolio. ANI also operates a generics and other pharmaceuticals segment, broadening its commercial reach across multiple therapeutic categories.

Manufacturing is a core competency. ANI offers contract manufacturing capabilities alongside its proprietary product lines, with quality systems and production facilities supporting both its own pipeline and third-party clients. Its operational footprint includes facilities in Baudette, Minnesota, and additional locations expanded through the acquisition of Novitium Pharma, which is now fully integrated into the ANI business.

The company maintains a medical information portal for both its branded rare disease products and its generics range, reflecting a commitment to supporting healthcare professionals with accurate prescribing resources. ANI reported first quarter 2026 financial results in May 2026 and raised its full-year 2026 financial guidance, signalling continued commercial momentum. The company was also scheduled to present at the 2026 Jefferies Global Healthcare Conference in May 2026.

Further information is available at anipharmaceuticals.com.

Areas of Expertise

Branded PharmaceuticalsContract ManufacturingDrug DevelopmentGeneric PharmaceuticalsRare DiseaseSpecialty Pharma

Services & Capabilities

Branded PharmaceuticalsContract ManufacturingDrug DevelopmentGeneric PharmaceuticalsRare DiseaseSpecialty Pharma
Similar Companies

More in Pharmaceutical Companies

A

Astellas Europe

Astellas Europe represents the regional operations of Astellas Pharma Inc., a Japanese global pharmaceutical company formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. Listed on the Tokyo Stock Exchange (ticker: 4503) and employing approximately 14,000 people worldwide, Astellas positions itself at the intersection of rigorous science and patient-centred value creation, with its European presence playing a significant role in clinical development, commercial operations, and medical affairs across the region. Therapy Areas and Commercial Portfolio The company's established commercial portfolio reflects a focused strategy across several specialist areas. In oncology and urology, enzalutamide (marketed as Xtandi) for metastatic prostate cancer stands as one of the group's flagship medicines, developed in partnership with Pfizer. Transplantation medicine remains a historical strength, with tacrolimus (Prograf) continuing to serve patients requiring immunosuppression following organ transplant. Overactive bladder is addressed through mirabegron (Betmiga), a beta-3 adrenoceptor agonist that expanded treatment options beyond established anticholinergic therapies. These products underpin the European business while the pipeline advances next-generation candidates. Research Priorities and Open Innovation Astellas concentrates its research investment on four primary scientific focuses: blindness and regeneration, genetic regulation, immuno-oncology, and targeted protein degradation. Drug discovery capabilities support candidate progression from early research through clinical trials, and external funding partnerships broaden the scope of scientific enquiry beyond internal capacity. Open innovation platforms, including the SakuLab facilities in Tsukuba and Cambridge and the TME iLab initiative, provide frameworks for collaboration with external researchers and institutions. Patient centricity is embedded structurally across the organisation, combining patient partnerships, medical intelligence, behavioural science expertise, and patient insights into a coherent programme that informs both the direction of science and standards of corporate governance. Manufacturing and supply operations complement the research enterprise, supporting the integrated model from discovery to commercial availability across European markets. Further information is available at astellas.com/eu/.

View profile
A

Allergy Therapeutics

Allergy Therapeutics positions itself as a global pioneer of convenient treatment for allergy and immune-related disorders, operating as a publicly listed company (PLC) with commercial presence across Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. A declared focus on patient convenience runs throughout the company's scientific and commercial model. The organisation frames convenience not as a secondary benefit but as a clinical imperative, recognising that treatment adherence in allergy immunotherapy depends on how manageable the regimen is for both healthcare professionals and patients. Its research and development programme reflects this, combining product development with a published body of investigator and consultant registry data. The company's adjuvant technology is commercialised through its Bencard Adjuvant Systems division, which sits alongside the core Allergy Therapeutics brand as a specialist unit serving healthcare partners and industry stakeholders. This dual structure signals a role that extends beyond direct-to-clinician supply into platform licensing and scientific collaboration. Investor-facing materials describe a defined business model, investment case, and strategy, consistent with a company that reports to public markets and maintains structured shareholder services. The breadth of its European footprint and the existence of a dedicated healthcare professional information channel indicate an established B2B and clinical relationships network. Further information is available at allergytherapeutics.com.

View profile
A

Accord Healthcare

Accord Healthcare ranks among the fastest-growing generic and biosimilar medicines companies in Europe, distributing products across more than 80 countries and holding one of the largest market footprints of any European generic pharmaceutical business. Established as the European commercial arm of Intas Pharmaceuticals, an Indian pharmaceutical group headquartered in Ahmedabad, Accord operates its principal EMENA base from Uxbridge, United Kingdom, with additional commercial representation in Barcelona, Spain, and a growing network of affiliates across Eastern Europe. Therapeutic Portfolio and European Reach Accord's product portfolio is built around hospital and community settings across several key therapy areas. Its oncology and haematology range forms the largest segment of the business, complemented by lines covering autoimmune conditions and central nervous system disorders. The company has delivered successive year-on-year growth in the volume of medicines launched across European markets, with its most recent annual cycle yielding the largest portfolio rollout in the company's history. A dedicated European affiliate network, with national teams across Austria, Czech Republic, Finland, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Slovakia, Spain and Sweden, provides the commercial infrastructure to support hospital tenders and retail pharmacy channels simultaneously. Biosimilars, Animal Health and Sustainability Beyond small-molecule generics, Accord Healthcare operates at the higher-complexity end of pharmaceutical development through its biosimilars programme, where regulatory pathways and development timelines mirror those of originator biologics. This positions the company among a relatively small group of European generics firms capable of competing in both chemical and biological medicine categories. Accord also maintains an animal health division, extending the group's reach across the broader life sciences sector, alongside a patient advocacy group function that signals engagement with patient outcomes beyond the purely commercial. The company publishes environment, social and governance reporting in line with expectations from institutional partners and regulated healthcare customers across the European Union and beyond. Further information is available at accord-healthcare.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy